PDP-716
Generic name: brimonidine tartrate
Treatment for: Glaucoma, Open Angle, Glaucoma/Intraocular Hypertension
FDA Issues Complete Response Letter for PDP-716 NDA Due to Inspection Findings at Third-Party API Manufacturing Facility
- No issues with clinical efficacy or safety were identified in the CRL
- No additional clinical data or trials have been requested
Mumbai, India, July 13, 2023 - Sun Pharma Advanced Research Company Ltd. (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872, "SPARC") today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PDP-716 for the treatment of patients with Glaucoma, due to inspection findings at a third-party Active Pharmaceutical Ingredient (API) manufacturing facility. The FDA did not raise any issues with the PDP-176 clinical efficacy or safety and no additional clinical data or trials have been requested. SPARC is committed to work closely with Visiox, the FDA and the third-party manufacturer to resubmit the NDA as quickly as possible.
About PDP-716
PDP-716 is a novel, once daily, ophthalmic suspension of brimonidine tartrate 0.35%. PDP-716 was developed using SPARC's proprietary TearActTM technology. SPARC had previously licensed global commercialization rights excluding India and China of PDP-716 to Visiox Pharmaceuticals Inc.
About Sun Pharma Advanced Research Company Ltd. (CIN - L73100GJ2006PLC047837)
Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC aims to advance availability of treatment options for patients across the world. More information about the company can be found at www.sparc.life
Disclaimer
Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.
Source: Sun Pharma Advanced Research Company
Posted: July 2023
Related articles
- Visiox Pharma Announces FDA Acceptance of New Drug Application for Glaucoma - December 8, 2022
- Visiox Pharma Submits New Drug Application Seeking Approval for First Once-Daily Brimonidine for Glaucoma - October 6, 2022
PDP-716 (brimonidine tartrate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.